DD209455A5 - Verfahren zur herstellung von ascorbinsaeureethern - Google Patents

Verfahren zur herstellung von ascorbinsaeureethern Download PDF

Info

Publication number
DD209455A5
DD209455A5 DD83247195A DD24719583A DD209455A5 DD 209455 A5 DD209455 A5 DD 209455A5 DD 83247195 A DD83247195 A DD 83247195A DD 24719583 A DD24719583 A DD 24719583A DD 209455 A5 DD209455 A5 DD 209455A5
Authority
DD
German Democratic Republic
Prior art keywords
ascorbic acid
alkyl
compound
formula
acid
Prior art date
Application number
DD83247195A
Other languages
German (de)
English (en)
Inventor
Gary A Koppel
Russell L Barton
Jesse R Bewley
Stephen L Briggs
Joseph W Parton
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DD209455A5 publication Critical patent/DD209455A5/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/62Three oxygen atoms, e.g. ascorbic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DD83247195A 1982-01-15 1983-01-12 Verfahren zur herstellung von ascorbinsaeureethern DD209455A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33934482A 1982-01-15 1982-01-15

Publications (1)

Publication Number Publication Date
DD209455A5 true DD209455A5 (de) 1984-05-09

Family

ID=23328588

Family Applications (1)

Application Number Title Priority Date Filing Date
DD83247195A DD209455A5 (de) 1982-01-15 1983-01-12 Verfahren zur herstellung von ascorbinsaeureethern

Country Status (16)

Country Link
EP (1) EP0086554A1 (el)
JP (1) JPS58131978A (el)
KR (1) KR840003247A (el)
AU (1) AU1035183A (el)
CA (1) CA1181078A (el)
DD (1) DD209455A5 (el)
DK (1) DK14283A (el)
ES (2) ES8403118A1 (el)
FI (1) FI830078L (el)
GB (1) GB2114571A (el)
GR (1) GR77897B (el)
IL (1) IL67646A0 (el)
PL (1) PL240125A1 (el)
PT (1) PT76083B (el)
RO (1) RO86439B (el)
ZA (1) ZA83173B (el)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552895A (en) * 1983-03-14 1985-11-12 Eli Lilly And Company Furo[3,2-b]furan-2-(3H)-ones
JPS6058973A (ja) * 1983-09-13 1985-04-05 Mitsubishi Yuka Yakuhin Kk γ−プチロラクトン誘導体及びそれを有効成分とする免疫調節剤
JPS60130582A (ja) * 1983-12-19 1985-07-12 Takeda Chem Ind Ltd 食品用酸化防止剤,アスコルビン酸誘導体およびその製造法
WO1986006720A1 (en) * 1985-05-17 1986-11-20 Takeda Chemical Industries, Ltd. Ascorbic acid derivatives, production thereof, and pharmaceutical preparation therefrom
WO1986007592A1 (en) * 1985-06-18 1986-12-31 Takeda Chemical Industries, Ltd. Ascorbic acid derivatives, process for their preparation, and preparations containing same
JPS60139619A (ja) * 1983-12-27 1985-07-24 Mutsuyuki Kochi O−ベンジリデン−アスコルビン酸又はその塩よりなる抗腫瘍剤
JP2515556B2 (ja) * 1986-08-29 1996-07-10 武田薬品工業株式会社 ヒドロキシブテノライド誘導体およびその製造法
JPH0730066B2 (ja) * 1988-03-09 1995-04-05 株式会社日本ハイポックス アスコルビン酸誘導体及びアスコルビン酸誘導体からなる抗酸化剤
JP2752080B2 (ja) * 1988-03-09 1998-05-18 株式会社日本ハイポックス アスコルビン酸誘導体及びその製造方法並びにアスコルビン酸誘導体からなる抗酸化剤
ATE150750T1 (de) 1988-09-01 1997-04-15 Takeda Chemical Industries Ltd Fumagillol-derivate
KR970002470B1 (ko) * 1989-09-11 1997-03-05 가부시끼가이샤 닛뽕하이폭스 아스코르빈산 유도체
US5095126A (en) * 1990-01-12 1992-03-10 Ohio State University Research Foundation Efficient synthesis for optically pure stereogenically labile 4-substituted-2-hydroxytetronic acids
US5210220A (en) * 1990-03-07 1993-05-11 Hoffmann-La Roche Inc. Method for preparing derivatives of ascorbic acid
EP0446539A1 (en) * 1990-03-16 1991-09-18 Merrell Dow Pharmaceuticals Inc. Novel ascorbic acid derivatives
US5270336A (en) * 1990-03-16 1993-12-14 Merrell Dow Pharmaceuticals Inc. Ascorbic acid derivatives
JPH0429989A (ja) * 1990-05-24 1992-01-31 Nisshin Flour Milling Co Ltd L―アスコルビン酸誘導体の製造法
GB9026114D0 (en) * 1990-11-30 1991-01-16 Norsk Hydro As New compounds
GB9201274D0 (en) * 1992-01-21 1992-03-11 Norsk Hydro As New compounds
GB9201275D0 (en) * 1992-01-21 1992-03-11 Norsk Hydro As New compounds
TW325997B (en) * 1993-02-02 1998-02-01 Senju Pharma Co Pharmaceutical composition for preventing and treating retinal diseases
US6114355A (en) * 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
DK1586322T3 (da) 1996-11-05 2008-12-01 Childrens Medical Center Sammensætninger indeholdende thalidomid og dextamethason til behandling af cancer
EP0875246A1 (en) * 1997-04-04 1998-11-04 Showa Denko Kabushiki Kaisha Pharmaceutical preparation of ascorbic acid derivatives for medical treatment of cancer
AU741933B2 (en) * 1998-03-27 2001-12-13 Lg Chemical Ltd. Polyethoxylated ascorbic acid derivatives as a novel antioxidant and process for preparing thereof
US6673828B1 (en) 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
WO2001056566A1 (fr) * 2000-02-01 2001-08-09 Mutsuyuki Kochi Compositions inhibitrices de neovascularisation et procede correspondant
CN1422157A (zh) * 2000-03-31 2003-06-04 安吉奥金尼药品有限公司 利用血管破坏活性的分割剂量疗法
DE60118625T2 (de) * 2001-07-26 2007-02-22 Tagra Biotechnologies Ltd. Stabilisierte ascorbinsäure -3- phosphat- derivate
TWI330533B (en) 2002-05-15 2010-09-21 Bhn Co Ltd Composition for angiogenesis inhibition, neoplasm inhibition,or immunostimulation
EP1939192A1 (en) * 2006-12-28 2008-07-02 Neuropharma S.A. Cyclopentanone derivatives, method of synthesis and uses thereof
FR2955493B1 (fr) * 2010-01-28 2012-02-24 Oreal Utilisation de derives d'acide ascorbique en coloration des fibres keratiniques humaines, composition les comprenant, procede de coloration et dispositif
JP5602456B2 (ja) * 2010-02-24 2014-10-08 日本精化株式会社 アスコルビン酸誘導体
US9550744B2 (en) * 2013-09-25 2017-01-24 University Of Florida Research Foundation, Inc. Vitamin C prodrugs and uses thereof
US10105407B2 (en) * 2015-06-09 2018-10-23 John P. Crow, JR. Methods of extraction of nitrosylated or nitrated derivatives of ascorbic acid from myriciaria dubia and methods of synthesis thereof
WO2017093354A1 (en) 2015-11-30 2017-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Nmdar antagonists for the treatment of diseases associated with angiogenesis

Also Published As

Publication number Publication date
DK14283A (da) 1983-07-16
RO86439A (ro) 1985-03-15
GB8300907D0 (en) 1983-02-16
ZA83173B (en) 1984-08-29
FI830078A0 (fi) 1983-01-10
GR77897B (el) 1984-09-25
FI830078L (fi) 1983-07-16
ES518968A0 (es) 1984-03-01
JPS58131978A (ja) 1983-08-06
IL67646A0 (en) 1983-05-15
PT76083A (en) 1983-02-01
KR840003247A (ko) 1984-08-20
PL240125A1 (en) 1984-04-24
CA1181078A (en) 1985-01-15
AU1035183A (en) 1983-07-21
RO86439B (ro) 1985-03-31
ES8403118A1 (es) 1984-03-01
ES525239A0 (es) 1985-01-16
ES8502698A1 (es) 1985-01-16
EP0086554A1 (en) 1983-08-24
DK14283D0 (da) 1983-01-14
PT76083B (en) 1986-01-09
GB2114571A (en) 1983-08-24

Similar Documents

Publication Publication Date Title
DD209455A5 (de) Verfahren zur herstellung von ascorbinsaeureethern
DE2915037C3 (de) Neue N-substituierte Moranolinderivate
DE69627042T2 (de) Isocumarinderivate und deren verwendung in medikamenten
US4552888A (en) Ascorbic acid ethers in angiogene
EP0247320A2 (de) 5-Arylalkyl-4-alkoxy-2(5H)-furanone, Zwischenprodukte und Verfahren zu ihrer Herstellung sowie ihre Anwendung als therapeutische Wirkstoffe
DE3788982T2 (de) Trans-6-[2-(N-heteroaryl)-3,5-disubstituiertes)pyrazol-4-yl)-ethyl] oder -ethenyl]tetrahydro-4-hydroxypyran-2-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung.
DE2923368A1 (de) Neue 5-fluor-( beta -uridin oder 2'-desoxy- beta -uridin)-derivate, verfahren zur herstellung derselben und carcinostatische mittel mit einem gehalt derselben
DE69811500T2 (de) Kristallmodifikation von 1-(2,6-difluorbenzyl)-1h-1,2,3-triazol-4-carbonsäureamid und seine verwendung als antiepileptikum
DE2839388A1 (de) Imidazolylvinylaether und deren verwendung
DE60131416T2 (de) Chirale fluochinolon-argininsalzformen
DE69623760T2 (de) Kaliumionen-kanal-blocker
DE69102477T2 (de) 3-Aminochroman-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen.
DE3438244C2 (el)
CH643830A5 (de) Bis-moranolin-derivate.
DE68905361T2 (de) Trienische Derivate mit chromenischer Struktur, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellungen.
DE3121175A1 (de) Erythro-1,2,3-triphenyl-1-pentanon-derivate sowie verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3709699C2 (de) 5-Fluoruracil-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
DE2723450A1 (de) Uracilderivate und verfahren zu ihrer herstellung
DE2909646B1 (de) N-Alkenylmoranolinderivate
DE2650231A1 (de) Neue imidazolverbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE69809564T2 (de) 2- 4-[4-(4,5-dichlor-2-methylimidazol-1-yl)butyl]piperazin-1-yl -5-fluorpyrimidin, seine herstellung und therapeutische verwendung
DE2932357A1 (de) Crotonamidderivate und sie enthaltende carcinostatische arzneimittel
DE1545581A1 (de) Neue Penicillinaldehyde und Verfahren zu deren Herstellung
CH687001A5 (de) Pharmazeutisches Praeparat zur Modulierung der Immunreaktion.
DE1795125C (de) Chinolinderivate, ein Verfahren zu ihrer Herstellung und Arzneimittel